Videos

"This trial did not require a biomarker for entry in, so patients were treated with combination therapy or standard care, which would have been the abiraterone alone, to see if there was a benefit," says Michael S. Cookson, MD, MMHC.

“The effect size for adjuvant nivolumab versus placebo across primary, secondary, and exploratory endpoints is all remarkably stable,” says Matthew D. Galsky, MD.

"The median survival of the combination arm was 16.1 months versus 13.4 months in the standard chemo arm," says Enrique Grande, MD.

“There are a number of trials that we're interested in to develop potentially combining chemotherapy and neoadjuvant immunotherapy,” says Joshua J. Meeks, MD, PhD.

"The MMAI model had significantly improved accuracy and prognostication to discriminate which patients would develop distant metastasis or die from prostate cancer," says Daniel E. Spratt, MD.

Expert perspectives on strategies to optimize communication, both between healthcare professionals and with patients who present with prostate cancer.

Cardiologist Anees A. Daud, MD, breaks down the typical patient with prostate cancer seen at his practice.

Urologist David Morris, MD, FACS, defines the typical patient with prostate cancer treated at his practice.

Oncologist Joelle Hamilton, MD, shares her perspective on the typical patient with prostate cancer seen at her institution.

Centering focus on a patient case of cardiovascular risk and prostate cancer, experts share their perspective on management strategies.

Comprehensive insight regarding strategies to mitigate cardiovascular risk in patients on therapy for prostate cancer.

Shared insight on a timeline of clinical studies contextualizing cardiovascular disease in the setting of prostate cancer management.

“I would ask the practicing urologist to keep an open mind and not be dogmatic about how they've practiced in the past, and to consider the multiple lines of both indirect and direct evidence that exist,” says Surena F. Matin, MD.

Expert perspectives on the risk of cardiovascular disease as it exists in the context of androgen deprivation therapy (ADT) and prostate cancer.

"We found that if the patient has normal IsoPSA, he has only 1% of risk of developing clinically significant prostate cancer in a median follow-up time of 18 months," says Nour Abdallah, MD.

“Same-day discharge after partial nephrectomy in properly selected patients is safe and cost effective for both patients and the health system,” says Andrew Wood, MD.

“HIFU also has gone up in its APC, so there's a higher reimbursement for the facility fees for hospital or ASC setting,” says Jonathan Rubenstein, MD.

"The reason that we really focus on prostate cancer is because it's amenable to early screening. Early detection is key in cure," says Janet Kukreja, MD, MPH, FACS.

“Based off the questionnaire, [there was] statistically significant worsening quality of life, increased pain, and [increased] pain medicine requirement with a stent compared to without a stent,” says Christopher Allam, MD.

"This scope allowed me to maintain the intrarenal pressures lower than I would originally have done," says Naeem Bhojani, MD, FRCSC.

“I am seeing this process rapidly expand, particularly with the use of the single-port robot, which offers additional benefits to things like pain control and helps to further expedite early discharge,” Andrew Wood, MD.

“There are a couple of nomograms that are good for predicting either T2 or higher disease at time of surgery, so on final pathology, or T3 or higher,” says Suzanne Lange, MD.

The patient presented with a large right renal mass who elected for right radical nephrectomy with possible inferior vena cava.

"The biggest take-home message for any urologist who's treating kidney stones is to understand that what we consider to be success may not be what our patients consider to be success," says John Michael DiBianco, MD.

"Before you even start your contract negotiation, I think it's really important to have a negotiation with yourself and understand what's important to you," says Siobhan M. Hartigan, MD.

“I would just burn it into everyone's brain that pain with intercourse is also going to be associated with genitourinary syndrome of menopause,” says Rachel Pope, MD, MPH.

Closing out his review of imaging modalities in the setting of prostate cancer, Brian Helfand, MD, PhD, looks toward future evolutions in detection and treatment.

Expert perspective on next steps for physicians and patients following a negative imaging result when recurrent prostate cancer is suspected.

Moving on to the second patient case of prostate cancer, Brian Helfand, MD, PhD, shares context for negative imaging results in this setting.

A brief discussion on how selection of imaging should be approached for patients receiving androgen deprivation therapy (ADT) for prostate cancer.